Arcutis Biotherapeutics
Commercial-stage medical dermatology company developing and commercializing targeted topical and biologic therapies for immune-mediated skin diseases. The company advances small-molecule topicals and biologics through preclinical and clinical development, pursues regulatory approvals and label expansions, conducts real-world and clinical research, and operates patient-access and digital health programs.
Industries
Nr. of Employees
large (251-1000)
Arcutis Biotherapeutics
Patents
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US-12697329-B2
View DetailsMethod for reducing side effects from administration of phosphodiesterase-4 inhibitors
US-12685727-B2
View DetailsPharmaceutical compositions of spironolactone for deep dermal drug delivery
US-12458652-B2
View DetailsMethod for reducing side effects from administration of phosphodiesterase-4 inhibitors
US-12390453-B2
View Details
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US-12697329-B2
View DetailsMethod for reducing side effects from administration of phosphodiesterase-4 inhibitors
US-12685727-B2
View DetailsPharmaceutical compositions of spironolactone for deep dermal drug delivery
US-12458652-B2
View DetailsMethod for reducing side effects from administration of phosphodiesterase-4 inhibitors
US-12390453-B2
View DetailsProducts
Topical roflumilast formulations (cream and foam)
Once-daily topical phosphodiesterase-4 (PDE4) inhibitor formulations in cream and foam vehicles, developed in multiple concentrations for treatment of inflammatory skin conditions.
Fusion-protein CD200R agonist (early clinical)
Investigational fusion-protein biologic acting as an agonist of the CD200 receptor in development for immune-mediated dermatologic diseases, intended to restore immune homeostasis via inhibitory signaling on immune cells.
Topical roflumilast formulations (cream and foam)
Once-daily topical phosphodiesterase-4 (PDE4) inhibitor formulations in cream and foam vehicles, developed in multiple concentrations for treatment of inflammatory skin conditions.
Fusion-protein CD200R agonist (early clinical)
Investigational fusion-protein biologic acting as an agonist of the CD200 receptor in development for immune-mediated dermatologic diseases, intended to restore immune homeostasis via inhibitory signaling on immune cells.
Services
Dissemination of clinical data at scientific meetings, investigator engagement, and provision of medical information to healthcare professionals.
Digital pathways connecting patients with independent, board-certified dermatologists and integrated telehealth platforms to facilitate evaluation, triage and access to topical therapies.
Combined patient access services and a patient assistance program that provide prescription support, co-pay assistance, financial-need-based medication programs and multiple application pathways (online, phone, downloadable form) to facilitate therapy access for eligible patients.
Medical education grants, sponsorships and administrative mechanisms for investigators to propose and run independent clinical studies.
Dissemination of clinical data at scientific meetings, investigator engagement, and provision of medical information to healthcare professionals.
Digital pathways connecting patients with independent, board-certified dermatologists and integrated telehealth platforms to facilitate evaluation, triage and access to topical therapies.
Combined patient access services and a patient assistance program that provide prescription support, co-pay assistance, financial-need-based medication programs and multiple application pathways (online, phone, downloadable form) to facilitate therapy access for eligible patients.
Medical education grants, sponsorships and administrative mechanisms for investigators to propose and run independent clinical studies.
Expertise Areas
- Clinical trial management (Phase 1–3)
- Pediatric dermatology development
- Topical and transdermal formulation development
- Biologic immunomodulator discovery and early development
Key Technologies
- Topical PDE4 inhibitor formulations (cream, foam)
- Topical formulation excipient optimization
- Fusion-protein CD200R agonist platform
- Pharmacokinetic and MUSE systemic exposure studies
News & Updates
Company presentation at a healthcare innovation investor conference.
Announcement of Q3 2026 financial results and webcast schedule.
FDA acceptance of a supplemental NDA to expand topical roflumilast cream indication to infants; supported by Phase 2 and Phase 1 PK data and assigned a PDUFA target action date.
Presentations of clinical trial subanalyses, infant trial data, and proteomic research; real-world surveys and literature reviews on topical corticosteroid use.
Quarterly financial report highlighting product revenue growth, regulatory approvals, pipeline enrollment milestones and launch of digital access initiatives.
Acquisition to obtain a preclinical CD200R agonist program to accelerate biologic development in atopic dermatitis.
Company presentation at a healthcare innovation investor conference.
Announcement of Q3 2026 financial results and webcast schedule.
FDA acceptance of a supplemental NDA to expand topical roflumilast cream indication to infants; supported by Phase 2 and Phase 1 PK data and assigned a PDUFA target action date.
Presentations of clinical trial subanalyses, infant trial data, and proteomic research; real-world surveys and literature reviews on topical corticosteroid use.
Quarterly financial report highlighting product revenue growth, regulatory approvals, pipeline enrollment milestones and launch of digital access initiatives.
Acquisition to obtain a preclinical CD200R agonist program to accelerate biologic development in atopic dermatitis.